ANGLE plc Asset Resilience Ratio
ANGLE plc asset resilience ratio. ANGLE plc (AGL) has an Asset Resilience Ratio of 33.24% as of June 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ANGLE plc (AGL) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of ANGLE plc (2004–2020)
Asset resilience ratio of ANGLE plc from 2004 to 2020. This chart shows how ANGLE plc's Asset Resilience Ratio has changed over time. Read how much debt does ANGLE plc carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down ANGLE plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ANGLE plc (AGL) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX11.55 Million | 33.24% |
| Total Liquid Assets | GBX11.55 Million | 33.24% |
Asset Resilience Insights
- Very High Liquidity: ANGLE plc maintains exceptional liquid asset reserves at 33.24% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ANGLE plc Industry Peers by Asset Resilience Ratio
Compare ANGLE plc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Vijaya Diagnostic Centre Limited
NSE:VIJAYA |
Diagnostics & Research | 15.15% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
ANGLE plc Asset Resilience Ratio by Year (2004–2020)
ANGLE plc asset resilience ratio by year from 2004 to 2020. The table below shows the annual Asset Resilience Ratio data for ANGLE plc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 42.35% | GBX16.54 Million ≈ $2.01K |
GBX39.05 Million ≈ $4.75K |
-6.74pp |
| 2019-12-31 | 49.09% | GBX15.01 Million ≈ $1.83K |
GBX30.57 Million ≈ $3.72K |
+27.82pp |
| 2013-04-30 | 21.27% | GBX1.60 Million ≈ $194.67 |
GBX7.52 Million ≈ $915.31 |
+24.24pp |
| 2012-04-30 | -2.97% | GBX-154.00K ≈ $-18.74 |
GBX5.18 Million ≈ $630.86 |
+25.58pp |
| 2011-04-30 | -28.55% | GBX-1.50 Million ≈ $-182.51 |
GBX5.25 Million ≈ $639.26 |
+0.12pp |
| 2010-04-30 | -28.67% | GBX-1.55 Million ≈ $-188.47 |
GBX5.40 Million ≈ $657.39 |
-37.83pp |
| 2009-04-30 | 9.16% | GBX499.00K ≈ $60.71 |
GBX5.45 Million ≈ $663.11 |
-2.19pp |
| 2008-04-30 | 11.35% | GBX1.04 Million ≈ $126.78 |
GBX9.18 Million ≈ $1.12K |
-12.05pp |
| 2007-04-30 | 23.40% | GBX1.81 Million ≈ $220.47 |
GBX7.74 Million ≈ $941.98 |
-6.79pp |
| 2006-04-30 | 30.20% | GBX4.87 Million ≈ $592.29 |
GBX16.12 Million ≈ $1.96K |
0.00pp |
| 2005-04-30 | 30.20% | GBX4.87 Million ≈ $592.29 |
GBX16.12 Million ≈ $1.96K |
+10.31pp |
| 2004-04-30 | 19.89% | GBX2.40 Million ≈ $291.77 |
GBX12.06 Million ≈ $1.47K |
-- |
About ANGLE plc
ANGLE plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis. It also provides Portrait+ C… Read more